Becton, Dickinson and Company (NYSE:BDX) Releases Quarterly Earnings Results, Beats Expectations By $0.04 EPS

by · The Cerbat Gem

Becton, Dickinson and Company (NYSE:BDX – Get Free Report) issued its quarterly earnings results on Thursday. The medical instruments supplier reported $3.81 earnings per share for the quarter, topping the consensus estimate of $3.77 by $0.04, RTT News reports. Becton, Dickinson and Company had a return on equity of 14.49% and a net margin of 7.13%. The firm had revenue of $5.44 billion during the quarter, compared to the consensus estimate of $5.38 billion. During the same period last year, the company earned $3.42 earnings per share. The company’s revenue for the quarter was up 6.9% on a year-over-year basis. Becton, Dickinson and Company updated its FY 2025 guidance to 14.250-14.600 EPS and its FY25 guidance to $14.25-14.60 EPS.

Becton, Dickinson and Company Trading Up 2.0 %

Shares of BDX stock opened at $231.64 on Friday. Becton, Dickinson and Company has a fifty-two week low of $218.75 and a fifty-two week high of $249.89. The stock has a market cap of $66.95 billion, a P/E ratio of 47.66, a P/E/G ratio of 1.80 and a beta of 0.43. The business has a fifty day simple moving average of $237.04 and a 200-day simple moving average of $235.09. The company has a quick ratio of 1.36, a current ratio of 1.85 and a debt-to-equity ratio of 0.70.

Becton, Dickinson and Company Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 31st. Stockholders of record on Monday, December 9th will be given a $1.04 dividend. The ex-dividend date is Monday, December 9th. This represents a $4.16 dividend on an annualized basis and a dividend yield of 1.80%. This is a boost from Becton, Dickinson and Company’s previous quarterly dividend of $0.95. Becton, Dickinson and Company’s dividend payout ratio (DPR) is currently 78.19%.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the company. Evercore ISI increased their price target on Becton, Dickinson and Company from $286.00 to $290.00 and gave the stock an “outperform” rating in a report on Tuesday, October 1st. Raymond James decreased their price target on Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating for the company in a report on Friday, August 2nd. Stifel Nicolaus raised their target price on Becton, Dickinson and Company from $270.00 to $280.00 and gave the company a “buy” rating in a report on Friday, July 26th. Citigroup raised Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and raised their target price for the company from $255.00 to $275.00 in a report on Tuesday, October 1st. Finally, StockNews.com raised Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a report on Thursday, August 8th. Nine equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Becton, Dickinson and Company currently has an average rating of “Buy” and a consensus price target of $282.63.

Get Our Latest Stock Analysis on BDX

About Becton, Dickinson and Company

(Get Free Report)

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.

Featured Stories